Postoperative Survival of Pulmonary Invasive Mucinous Adenocarcinoma Versus Non-mucinous Invasive Adenocarcinoma

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2023 Jan 9

PMID 36624430

Authors

Dongyu Cui

Shaonan Xie

Qingyi Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: In 2015, the World Health Organization renamed mucinous bronchioloalveolar adenocarcinoma as pulmonary invasive mucinous adenocarcinoma (IMA). Due to its low incidence and unclear prognosis with surgical treatment, previous studies have presented opposing survival outcomes. We aimed to investigate the differences in surgical prognosis and prognosis-related risk factors by comparing IMA with non-mucinous invasive adenocarcinoma (NMA).

Methods: A total of 20,914 patients diagnosed with IMA or NMA from 2000 to 2014 were screened from the Surveillance, Epidemiology, and End Results database. The screened patients were subjected to propensity score matching (PSM) in a 1:4 ratio to explore the survival differences between patients with IMA and NMA and the factors influencing prognosis.

Results: For all patients, IMA was prevalent in the lower lobes of the lungs (p < 0.0001), well-differentiated histologically (p < 0.0001), less likely to have lymph node metastases (94.4% vs. 72.0%, p < 0.0001) and at an earlier pathological stage (p = 0.0001). After PSM, the IMA cohort consisted of 303 patients, and the NMA cohort consisted of 1212 patients. Kaplan‒Meier survival analysis showed no difference in overall survival (OS) between patients in the IMA cohort and those in the NMA cohort (p = 0.7). Cox proportional hazards analysis showed that differences in tumor pathological type did not influence OS between the two cohorts (p = 0.65). Age (HR: 1.98, 95% CI 1.7-2.31, p < 0.0001), gender (HR: 0.64, 95% CI 0.55-0.75, p < 0.0001), and radiation treatment (HR: 2.49, 95% CI 1.84-3.37, p < 0.0001) were independent predictors of patient OS.

Conclusion: There was no significant difference in OS between patients with IMA and those with NMA after surgical treatment. Age, sex, and radiation treatment can independently predict OS.

Citing Articles

Sublobectomy versus lobectomy for peripheral small-sized pulmonary mucinous adenocarcinoma.

Yang Z, Yang F, Li Z, Fernando H, Li X, Jiang G J Thorac Dis. 2025; 17(1):390-399.

PMID: 39975724 PMC: 11833556. DOI: 10.21037/jtd-2024-2096.

Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma.

Zou J, Han W, Hu Y, Zeng C, Li J, Lei W World J Surg Oncol. 2025; 23(1):16.

PMID: 39844176 PMC: 11752792. DOI: 10.1186/s12957-025-03680-x.

Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma).

Chae Y, Othus M, Patel S, Gerber D, Tanvetyanon T, Kim H Ther Adv Med Oncol. 2024; 16:17588359241293401.

PMID: 39583952 PMC: 11583498. DOI: 10.1177/17588359241293401.

Pulmonary mucinous adenocarcinoma: An overview of pathophysiology and advancements in treatment.

Ge L, Wang L, Pei D Heliyon. 2024; 10(9):e28881.

PMID: 38694119 PMC: 11058725. DOI: 10.1016/j.heliyon.2024.e28881.

HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies.

Xie Y, Ye J, Luo H Onco Targets Ther. 2023; 16:849-865.

PMID: 37899986 PMC: 10612484. DOI: 10.2147/OTT.S425523.

References

Leir S, Harris A . MUC6 mucin expression inhibits tumor cell invasion. Exp Cell Res. 2011; 317(17):2408-19. DOI: 10.1016/j.yexcr.2011.07.021. View

Hwang D, Sholl L, Rojas-Rudilla V, Hall D, Shivdasani P, Garcia E . KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung. J Thorac Oncol. 2016; 11(4):496-503. DOI: 10.1016/j.jtho.2016.01.010. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Yanagawa N, Shiono S, Abiko M, Ogata S, Sato T, Tamura G . New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. J Thorac Oncol. 2013; 8(5):612-8. DOI: 10.1097/JTO.0b013e318287c3eb. View

Wislez M, Antoine M, Baudrin L, Poulot V, Neuville A, Pradere M . Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer. 2009; 68(2):185-91. DOI: 10.1016/j.lungcan.2009.05.021. View

Kakegawa S, Shimizu K, Sugano M, Miyamae Y, Kaira K, Araki T . Clinicopathological features of lung adenocarcinoma with KRAS mutations. Cancer. 2011; 117(18):4257-66. DOI: 10.1002/cncr.26010. View

Hata A, Katakami N, Fujita S, Kaji R, Imai Y, Takahashi Y . Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. J Thorac Oncol. 2010; 5(8):1197-200. DOI: 10.1097/JTO.0b013e3181e2a2bc. View

Tang E, Schreiner A, Pua B . Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS). J Thorac Dis. 2014; 6(Suppl 5):S489-501. PMC: 4209385. DOI: 10.3978/j.issn.2072-1439.2014.09.12. View

Xu X, Shen W, Wang D, Li N, Huang Z, Sheng J . Clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma. Transl Lung Cancer Res. 2022; 11(3):420-431. PMC: 8988085. DOI: 10.21037/tlcr-22-190. View

10.

Wang Y, Liu J, Huang C, Zeng Y, Liu Y, Du J . Development and validation of a nomogram for predicting survival of pulmonary invasive mucinous adenocarcinoma based on surveillance, epidemiology, and end results (SEER) database. BMC Cancer. 2021; 21(1):148. PMC: 7877040. DOI: 10.1186/s12885-021-07811-x. View

11.

Lee H, Cha M, Lee K, Lee H, Kwon O, Choi J . Prognosis in Resected Invasive Mucinous Adenocarcinomas of the Lung: Related Factors and Comparison with Resected Nonmucinous Adenocarcinomas. J Thorac Oncol. 2016; 11(7):1064-73. DOI: 10.1016/j.jtho.2016.03.011. View

12.

Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M . Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res. 2014; 20(12):3087-93. PMC: 6329293. DOI: 10.1158/1078-0432.CCR-14-0107. View

13.

Luo J, Wang R, Han B, Zhang J, Zhao H, Fang W . Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma. J Cancer Res Clin Oncol. 2016; 142(8):1837-45. DOI: 10.1007/s00432-016-2201-9. View

14.

Chen Z, Li M, Ma K, Shang G, Liang J, Yin J . Analysis of the clinicopathological characteristics, genetic phenotypes, and prognostic of pure mucinous adenocarcinoma. Cancer Med. 2019; 9(2):517-529. PMC: 6970056. DOI: 10.1002/cam4.2726. View

15.

Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F . CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov. 2014; 4(4):415-22. DOI: 10.1158/2159-8290.CD-13-0633. View

16.

Marx A, Chan J, Coindre J, Detterbeck F, Girard N, Harris N . The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. J Thorac Oncol. 2015; 10(10):1383-95. PMC: 4581965. DOI: 10.1097/JTO.0000000000000654. View

17.

Russell P, Wainer Z, Wright G, Daniels M, Conron M, Williams R . Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung.... J Thorac Oncol. 2011; 6(9):1496-504. DOI: 10.1097/JTO.0b013e318221f701. View

18.

Liu Y, Zhang H, Mei J, Guo Y, Li R, Wei S . Primary mucinous adenocarcinoma of the lung: A case report and review of the literature. Oncol Lett. 2017; 14(3):3701-3704. PMC: 5587939. DOI: 10.3892/ol.2017.6615. View

19.

Deng C, Zhang Y, Ma Z, Fu F, Deng L, Li Y . Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma. J Thorac Cardiovasc Surg. 2020; 162(3):664-674.e7. DOI: 10.1016/j.jtcvs.2020.05.099. View

20.

Blons H, Cote J, Le Corre D, Riquet M, Fabre-Guilevin E, Laurent-Puig P . Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. Am J Surg Pathol. 2006; 30(10):1309-15. DOI: 10.1097/01.pas.0000213285.65907.31. View